Condition: Solid Tumors · Sponsor: Hansoh BioMedical R&D Company
This is an open-label, multicenter study to evaluate the safety and tolerability of HS-20110 in participants with advanced solid malignant tumors
This description comes directly from the study's public registry record.
Hongyan Wang · 15111915273 · wanghy10@hspharm.com
Amanda Guo · guoj9@hspharm.com
Always discuss trial participation with your own doctor first.
| BRCR Medical Center INC | Tamarac, Florida, United States | Recruiting |
| Fort Wayne Medical Oncology and Hematology | Fort Wayne, Indiana, United States | Recruiting |
| Carolina BioOncology Institute | Huntersville, North Carolina, United States | Recruiting |
| The University of Texas MD Anderson Cancer Center | Houston, Texas, United States | Recruiting |
| NEXT Dallas | Irving, Texas, United States | Recruiting |
| NEXT Oncology | San Antonio, Texas, United States | Recruiting |
| NEXT Virginia | Fairfax, Virginia, United States | Recruiting |
| SUN YAT-SEN University Cancer Center | Guangzhou, Guangdong, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06892379